The global CINV Existing and Pipeline Drugs market size was valued at USD 1562.2 million in 2023 and is forecast to a readjusted size of USD 1929.5 million by 2030 with a CAGR of 3.1% during review period.
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report includes an overview of the development of the CINV Existing and Pipeline Drugs industry chain, the market status of Hospitals (Aloxi, Zofran Generic), Specialty Clinics (Aloxi, Zofran Generic), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of CINV Existing and Pipeline Drugs.
Regionally, the report analyzes the CINV Existing and Pipeline Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global CINV Existing and Pipeline Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the CINV Existing and Pipeline Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the CINV Existing and Pipeline Drugs industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (Kg), revenue generated, and market share of different by Type (e.g., Aloxi, Zofran Generic).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the CINV Existing and Pipeline Drugs market.
Regional Analysis: The report involves examining the CINV Existing and Pipeline Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the CINV Existing and Pipeline Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to CINV Existing and Pipeline Drugs:
Company Analysis: Report covers individual CINV Existing and Pipeline Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards CINV Existing and Pipeline Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Specialty Clinics).
Technology Analysis: Report covers specific technologies relevant to CINV Existing and Pipeline Drugs. It assesses the current state, advancements, and potential future developments in CINV Existing and Pipeline Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the CINV Existing and Pipeline Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
CINV Existing and Pipeline Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
麻豆原创 segment by Type
Aloxi
Zofran Generic
Kytril Generic
Emend
Akynzeo
SUSTOL
Rolapitant
麻豆原创 segment by Application
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Major players covered
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe CINV Existing and Pipeline Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of CINV Existing and Pipeline Drugs, with price, sales, revenue and global market share of CINV Existing and Pipeline Drugs from 2019 to 2024.
Chapter 3, the CINV Existing and Pipeline Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the CINV Existing and Pipeline Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and CINV Existing and Pipeline Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of CINV Existing and Pipeline Drugs.
Chapter 14 and 15, to describe CINV Existing and Pipeline Drugs sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of CINV Existing and Pipeline Drugs
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global CINV Existing and Pipeline Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Aloxi
1.3.3 Zofran Generic
1.3.4 Kytril Generic
1.3.5 Emend
1.3.6 Akynzeo
1.3.7 SUSTOL
1.3.8 Rolapitant
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global CINV Existing and Pipeline Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospitals
1.4.3 Specialty Clinics
1.4.4 Diagnostic Centers Therapeutics
1.4.5 Hospital Pharmacies
1.4.6 Drugstores
1.5 Global CINV Existing and Pipeline Drugs 麻豆原创 Size & Forecast
1.5.1 Global CINV Existing and Pipeline Drugs Consumption Value (2019 & 2023 & 2030)
1.5.2 Global CINV Existing and Pipeline Drugs Sales Quantity (2019-2030)
1.5.3 Global CINV Existing and Pipeline Drugs Average Price (2019-2030)
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 GlaxoSmithKline Details
2.1.2 GlaxoSmithKline Major Business
2.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Product and Services
2.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 GlaxoSmithKline Recent Developments/Updates
2.2 Helsinn
2.2.1 Helsinn Details
2.2.2 Helsinn Major Business
2.2.3 Helsinn CINV Existing and Pipeline Drugs Product and Services
2.2.4 Helsinn CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Helsinn Recent Developments/Updates
2.3 Heron Therapeutics
2.3.1 Heron Therapeutics Details
2.3.2 Heron Therapeutics Major Business
2.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Product and Services
2.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Heron Therapeutics Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck CINV Existing and Pipeline Drugs Product and Services
2.4.4 Merck CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Merck Recent Developments/Updates
2.5 Tesaro
2.5.1 Tesaro Details
2.5.2 Tesaro Major Business
2.5.3 Tesaro CINV Existing and Pipeline Drugs Product and Services
2.5.4 Tesaro CINV Existing and Pipeline Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Tesaro Recent Developments/Updates
3 Competitive Environment: CINV Existing and Pipeline Drugs by Manufacturer
3.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Manufacturer (2019-2024)
3.2 Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2019-2024)
3.3 Global CINV Existing and Pipeline Drugs Average Price by Manufacturer (2019-2024)
3.4 麻豆原创 Share Analysis (2023)
3.4.1 Producer Shipments of CINV Existing and Pipeline Drugs by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2023
3.4.2 Top 3 CINV Existing and Pipeline Drugs Manufacturer 麻豆原创 Share in 2023
3.4.2 Top 6 CINV Existing and Pipeline Drugs Manufacturer 麻豆原创 Share in 2023
3.5 CINV Existing and Pipeline Drugs 麻豆原创: Overall Company Footprint Analysis
3.5.1 CINV Existing and Pipeline Drugs 麻豆原创: Region Footprint
3.5.2 CINV Existing and Pipeline Drugs 麻豆原创: Company Product Type Footprint
3.5.3 CINV Existing and Pipeline Drugs 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global CINV Existing and Pipeline Drugs 麻豆原创 Size by Region
4.1.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2030)
4.1.2 Global CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2030)
4.1.3 Global CINV Existing and Pipeline Drugs Average Price by Region (2019-2030)
4.2 North America CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.3 Europe CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.4 Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.5 South America CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
4.6 Middle East and Africa CINV Existing and Pipeline Drugs Consumption Value (2019-2030)
5 麻豆原创 Segment by Type
5.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
5.2 Global CINV Existing and Pipeline Drugs Consumption Value by Type (2019-2030)
5.3 Global CINV Existing and Pipeline Drugs Average Price by Type (2019-2030)
6 麻豆原创 Segment by Application
6.1 Global CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
6.2 Global CINV Existing and Pipeline Drugs Consumption Value by Application (2019-2030)
6.3 Global CINV Existing and Pipeline Drugs Average Price by Application (2019-2030)
7 North America
7.1 North America CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
7.2 North America CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
7.3 North America CINV Existing and Pipeline Drugs 麻豆原创 Size by Country
7.3.1 North America CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
7.3.2 North America CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
7.3.3 United States 麻豆原创 Size and Forecast (2019-2030)
7.3.4 Canada 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Mexico 麻豆原创 Size and Forecast (2019-2030)
8 Europe
8.1 Europe CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
8.2 Europe CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
8.3 Europe CINV Existing and Pipeline Drugs 麻豆原创 Size by Country
8.3.1 Europe CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
8.3.2 Europe CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
8.3.3 Germany 麻豆原创 Size and Forecast (2019-2030)
8.3.4 France 麻豆原创 Size and Forecast (2019-2030)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Russia 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Italy 麻豆原创 Size and Forecast (2019-2030)
9 Asia-Pacific
9.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific CINV Existing and Pipeline Drugs 麻豆原创 Size by Region
9.3.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific CINV Existing and Pipeline Drugs Consumption Value by Region (2019-2030)
9.3.3 China 麻豆原创 Size and Forecast (2019-2030)
9.3.4 Japan 麻豆原创 Size and Forecast (2019-2030)
9.3.5 Korea 麻豆原创 Size and Forecast (2019-2030)
9.3.6 India 麻豆原创 Size and Forecast (2019-2030)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2019-2030)
9.3.8 Australia 麻豆原创 Size and Forecast (2019-2030)
10 South America
10.1 South America CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
10.2 South America CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
10.3 South America CINV Existing and Pipeline Drugs 麻豆原创 Size by Country
10.3.1 South America CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
10.3.2 South America CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
10.3.3 Brazil 麻豆原创 Size and Forecast (2019-2030)
10.3.4 Argentina 麻豆原创 Size and Forecast (2019-2030)
11 Middle East & Africa
11.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa CINV Existing and Pipeline Drugs 麻豆原创 Size by Country
11.3.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa CINV Existing and Pipeline Drugs Consumption Value by Country (2019-2030)
11.3.3 Turkey 麻豆原创 Size and Forecast (2019-2030)
11.3.4 Egypt 麻豆原创 Size and Forecast (2019-2030)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2019-2030)
11.3.6 South Africa 麻豆原创 Size and Forecast (2019-2030)
12 麻豆原创 Dynamics
12.1 CINV Existing and Pipeline Drugs 麻豆原创 Drivers
12.2 CINV Existing and Pipeline Drugs 麻豆原创 Restraints
12.3 CINV Existing and Pipeline Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of CINV Existing and Pipeline Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of CINV Existing and Pipeline Drugs
13.3 CINV Existing and Pipeline Drugs Production Process
13.4 CINV Existing and Pipeline Drugs Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 CINV Existing and Pipeline Drugs Typical Distributors
14.3 CINV Existing and Pipeline Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
听
听
*If Applicable.
